FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average t	ourden								
- 1	hours nor rosponsos	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						i Section	JII 301	(1) 01 111	e iiives	Suneni	Company Ac	1 01 1940									
Name and Address of Reporting Person* Maduck Sean						2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify						
	`	irst) ERAPEUTICS	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 09/01/2021									X Officer (give title Other (specify below) Chief Commercial Officer						
149 COMMONWEALTH DRIVE																	Joint/Group Filing (Check Applicable				
(Street) MENLO PARK CA 94025															X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	state)	(Zip)																		
		Tab	ole I -	Non-Der	ivativ	e Sec	curit	ties A	cquir	red, [Disposed	of, or I	3enefi	cially	Owned						
		Date	Transaction ate lonth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)			Transaction Disposed Of (Code (Instr.		Acquired (A) or (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) or (D)	Price		Reported Transacti (Instr. 3 a	ion(s)			(Instr. 4)		
Common Stock 09/01/2021				021	1		M ⁽¹⁾		25,000	A	\$3.	.29	65,0)24	24 D						
Common	ommon Stock 09/01/202			021	1		S ⁽¹⁾		25,000	D	\$21.3	3972 ⁽²⁾ 4		,024		D					
Common Stock														10,0	000			See Footnote ⁽³⁾			
Common Stock													10,00		1 000			See Footnote ⁽⁴⁾			
		•	Table								sposed of				Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year) if	Execu			action (Instr.			Expi (Mor	ate Exe iration nth/Day		7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transacti (Instr. 4)	e Own s Form ally Direc or In g (I) (Ir	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)		
					Code	ode V	(A)	(D)	Date Exer	: rcisable	Expiration Date	Title	or Nur of	ount mber ures							
Stock Option (Right to	\$3.29	09/01/2021			M ⁽¹⁾			25,000		(5)	02/18/2025	Comm		,000	\$0.00	147,6	502	D			

Explanation of Responses:

- 1. The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.
- 2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from \$21.38 to \$21.445 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
- 3. Represents the shares held by Duckhill Capital, LLC of which the reporting person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
- 4. Represents the shares held by Sean and Molly Maduck Living Trust of which the reporting person is a co-trustee.
- 5. Fully exercisable.

Remarks:

/s/ Joseph Douglas Lyon, Attorney-in-Fact for Sean **Nicholas**

09/03/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.